Last reviewed · How we verify

TMX-SMX (Bactrim(R)) — Competitive Intelligence Brief

TMX-SMX (Bactrim(R)) (TMX-SMX (Bactrim(R))) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sulfonamide antibiotic combination. Area: Infectious Disease.

marketed Sulfonamide antibiotic combination Dihydrofolate reductase; dihydropteroate synthase Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

TMX-SMX (Bactrim(R)) (TMX-SMX (Bactrim(R))) — Department of Medical Services Ministry of Public Health of Thailand. TMX-SMX (trimethoprim-sulfamethoxazole) is a fixed-dose combination antibiotic that inhibits bacterial folate synthesis by blocking dihydrofolate reductase and dihydropteroate synthase.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
TMX-SMX (Bactrim(R)) TARGET TMX-SMX (Bactrim(R)) Department of Medical Services Ministry of Public Health of Thailand marketed Sulfonamide antibiotic combination Dihydrofolate reductase; dihydropteroate synthase
Quinine plus sulfadoxine-pyrimethamine Quinine plus sulfadoxine-pyrimethamine Albert Schweitzer Hospital marketed Antimalarial combination Plasmodium DNA/protein synthesis; dihydrofolate reductase; dihydropteroate synthase
Sulphadoxine-Pyrimethamine Sulphadoxine-Pyrimethamine ORIYOMI OMOTOYOSI AKINYOTU marketed Antifolate antimalarial Dihydrofolate reductase; dihydropteroate synthase
Sulfadoxine-pyrimethamine/folic acid Sulfadoxine-pyrimethamine/folic acid Centers for Disease Control and Prevention marketed Antifolate antimalarial Dihydrofolate reductase; dihydropteroate synthase
Sulfadoxine pyrimethamine Sulfadoxine pyrimethamine Radboud University Medical Center marketed Antifolate antimalarial Dihydrofolate reductase; dihydropteroate synthase
Artesunate + Sulfadoxine-Pyrimethamine Artesunate + Sulfadoxine-Pyrimethamine Sanofi marketed Antimalarial combination Plasmodium falciparum (multiple targets: artemisinin-induced oxidative stress; dihydrofolate reductase; dihydropteroate synthase)
IPTp-sulphadoxine-pyrimethamine IPTp-sulphadoxine-pyrimethamine London School of Hygiene and Tropical Medicine phase 3 Antifolate antimalarial combination Dihydrofolate reductase; Dihydropteroate synthase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sulfonamide antibiotic combination class)

  1. Khon Kaen University · 2 drugs in this class
  2. Department of Medical Services Ministry of Public Health of Thailand · 1 drug in this class
  3. Fundacion Clinic per a la Recerca Biomédica · 1 drug in this class
  4. National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
  5. University of Oxford · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TMX-SMX (Bactrim(R)) — Competitive Intelligence Brief. https://druglandscape.com/ci/tmx-smx-bactrim-r. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: